Stimulating severe COVID-19: the potential role of GM-CSF antagonism
- PMID: 34863335
- PMCID: PMC8635456
- DOI: 10.1016/S2213-2600(21)00539-7
Stimulating severe COVID-19: the potential role of GM-CSF antagonism
Conflict of interest statement
We declare no competing interests.
Comment on
-
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1. Lancet Respir Med. 2022. PMID: 34863332 Free PMC article. Clinical Trial.
References
-
- Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16:126–133. - PubMed
-
- van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17:407–420. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical